Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes.

Salomon MP, Wang X, Marzese DM, Hsu SC, Nelson N, Zhang X, Matsuba C, Takasumi Y, Ballesteros-Merino C, Fox BA, Barkhoudarian G, Kelly DF, Hoon DSB.

Clin Cancer Res. 2018 Jul 3. doi: 10.1158/1078-0432.CCR-17-2206. [Epub ahead of print]

PMID:
30084836
2.

Novel frontiers in detecting cancer metastasis.

Leong SP, Ballesteros-Merino C, Jensen SM, Marwitz S, Bifulco C, Fox BA, Skoberne M.

Clin Exp Metastasis. 2018 Jul 18. doi: 10.1007/s10585-018-9918-6. [Epub ahead of print] Review.

PMID:
30022365
3.

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.

Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, Chang SC, Grunkemeier G, Leidner R, Bell RB, Weinberg AD.

Nat Commun. 2018 Jul 13;9(1):2724. doi: 10.1038/s41467-018-05072-0.

4.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

5.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, Geppert C, Kolwelter J, Merkel S, Grützmann R, Van den Eynde M, Jouret-Mourin A, Kartheuser A, Léonard D, Remue C, Wang JY, Bavi P, Roehrl MHA, Ohashi PS, Nguyen LT, Han S, MacGregor HL, Hafezi-Bakhtiari S, Wouters BG, Masucci GV, Andersson EK, Zavadova E, Vocka M, Spacek J, Petruzelka L, Konopasek B, Dundr P, Skalova H, Nemejcova K, Botti G, Tatangelo F, Delrio P, Ciliberto G, Maio M, Laghi L, Grizzi F, Fredriksen T, Buttard B, Angelova M, Vasaturo A, Maby P, Church SE, Angell HK, Lafontaine L, Bruni D, El Sissy C, Haicheur N, Kirilovsky A, Berger A, Lagorce C, Meyers JP, Paustian C, Feng Z, Ballesteros-Merino C, Dijkstra J, van de Water C, van Lent-van Vliet S, Knijn N, Mușină AM, Scripcariu DV, Popivanova B, Xu M, Fujita T, Hazama S, Suzuki N, Nagano H, Okuno K, Torigoe T, Sato N, Furuhata T, Takemasa I, Itoh K, Patel PS, Vora HH, Shah B, Patel JB, Rajvik KN, Pandya SJ, Shukla SN, Wang Y, Zhang G, Kawakami Y, Marincola FM, Ascierto PA, Sargent DJ, Fox BA, Galon J.

Lancet. 2018 May 26;391(10135):2128-2139. doi: 10.1016/S0140-6736(18)30789-X. Epub 2018 May 10.

PMID:
29754777
6.

Validation of a Host Response Assay, Septicyte™ LAB, for Discriminating Sepsis from SIRS in the ICU.

Miller Iii RR, Lopansri BK, Burke JP, Levy M, Opal S, Rothman RE, D'Alessio FR, Sidhaye VK, Aggarwal NR, Balk R, Greenberg JA, Yoder M, Patel G, Gilbert E, Afshar M, Parada JP, Martin GS, Esper AM, Kempker JA, Narasimhan M, Tsegaye A, Hahn S, Mayo P, van der Poll T, Schultz MJ, Scicluna BP, Klein Klouwenberg P, Rapisarda A, Seldon TA, McHugh LC, Yager TD, Cermelli S, Sampson D, Rothwell V, Newman R, Bhide S, Fox BA, Kirk JT, Navalkar K, Davis RF, Brandon RA, Brandon RB.

Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201712-2472OC. [Epub ahead of print]

PMID:
29624409
7.

Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination.

Hulett TW, Jensen SM, Wilmarth PA, Reddy AP, Ballesteros-Merino C, Afentoulis ME, Dubay C, David LL, Fox BA.

J Immunother Cancer. 2018 Apr 5;6(1):27. doi: 10.1186/s40425-018-0331-0.

8.

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2018 Feb 15;13(2):e0192988. doi: 10.1371/journal.pone.0192988. eCollection 2018.

9.

MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.

Rozanov DV, Rozanov ND, Chiotti KE, Reddy A, Wilmarth PA, David LL, Cha SW, Woo S, Pevzner P, Bafna V, Burrows GG, Rantala JK, Levin T, Anur P, Johnson-Camacho K, Tabatabaei S, Munson DJ, Bruno TC, Slansky JE, Kappler JW, Hirano N, Boegel S, Fox BA, Egelston C, Simons DL, Jimenez G, Lee PP, Gray JW, Spellman PT.

J Proteomics. 2018 Mar 30;176:13-23. doi: 10.1016/j.jprot.2018.01.004. Epub 2018 Jan 10.

10.

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.

Sanborn RE, Ross HJ, Aung S, Acheson A, Moudgil T, Puri S, Hilton T, Fisher B, Coffey T, Paustian C, Neuberger M, Walker E, Hu HM, Urba WJ, Fox BA.

J Immunother Cancer. 2017 Dec 19;5(1):103. doi: 10.1186/s40425-017-0306-6.

11.

Relationships matter in oral cancer: will single-stain immunohistochemistry become irrelevant in the age of multispectral imaging?

Bell RB, Fox BA.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Dec;124(6):517-518. doi: 10.1016/j.oooo.2017.09.010. Epub 2017 Sep 28. No abstract available.

PMID:
29169510
12.

STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2017 Nov 14;12(11):e0187532. doi: 10.1371/journal.pone.0187532. eCollection 2017. Erratum in: PLoS One. 2018 Feb 15;13(2):e0192988.

13.

The need for a network to establish and validate predictive biomarkers in cancer immunotherapy.

Masucci GV, Cesano A, Eggermont A, Fox BA, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA.

J Transl Med. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2.

14.

Cancer therapy in a microbial bottle: Uncorking the novel biology of the protozoan Toxoplasma gondii.

Fox BA, Butler KL, Guevara RB, Bzik DJ.

PLoS Pathog. 2017 Sep 14;13(9):e1006523. doi: 10.1371/journal.ppat.1006523. eCollection 2017 Sep. Review. No abstract available.

15.

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.

Clin Cancer Res. 2017 Oct 15;23(20):6165-6177. doi: 10.1158/1078-0432.CCR-16-2677. Epub 2017 Aug 28.

PMID:
28855348
16.

Multiparametric immune profiling in HPV- oral squamous cell cancer.

Feng Z, Bethmann D, Kappler M, Ballesteros-Merino C, Eckert A, Bell RB, Cheng A, Bui T, Leidner R, Urba WJ, Johnson K, Hoyt C, Bifulco CB, Bukur J, Wickenhauser C, Seliger B, Fox BA.

JCI Insight. 2017 Jul 20;2(14). pii: 93652. doi: 10.1172/jci.insight.93652. [Epub ahead of print]

17.

Genome sequence of a diabetes-prone rodent reveals a mutation hotspot around the ParaHox gene cluster.

Hargreaves AD, Zhou L, Christensen J, Marlétaz F, Liu S, Li F, Jansen PG, Spiga E, Hansen MT, Pedersen SVH, Biswas S, Serikawa K, Fox BA, Taylor WR, Mulley JF, Zhang G, Heller RS, Holland PWH.

Proc Natl Acad Sci U S A. 2017 Jul 18;114(29):7677-7682. doi: 10.1073/pnas.1702930114. Epub 2017 Jul 3.

18.

Immunotherapy biomarkers 2016: overcoming the barriers.

Gulley JL, Berzofsky JA, Butler MO, Cesano A, Fox BA, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH.

J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.

19.

A Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other Etiologies.

Sampson DL, Fox BA, Yager TD, Bhide S, Cermelli S, McHugh LC, Seldon TA, Brandon RA, Sullivan E, Zimmerman JJ, Noursadeghi M, Brandon RB.

Sci Rep. 2017 Jun 6;7(1):2914. doi: 10.1038/s41598-017-02325-8.

20.

Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.

Yu G, Moudgil T, Cui Z, Mou Y, Wang L, Fox BA, Hu HM.

J Immunother. 2017 Jun;40(5):155-163. doi: 10.1097/CJI.0000000000000165.

PMID:
28368960
21.

Lactate dehydrogenase in Toxoplasma gondii controls virulence, bradyzoite differentiation, and chronic infection.

Abdelbaset AE, Fox BA, Karram MH, Abd Ellah MR, Bzik DJ, Igarashi M.

PLoS One. 2017 Mar 21;12(3):e0173745. doi: 10.1371/journal.pone.0173745. eCollection 2017.

22.

Immunoprofiling as a predictor of patient's response to cancer therapy-promises and challenges.

Bethmann D, Feng Z, Fox BA.

Curr Opin Immunol. 2017 Apr;45:60-72. doi: 10.1016/j.coi.2017.01.005. Epub 2017 Feb 20. Review.

PMID:
28222333
23.

Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].

Bell RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2017 Mar;66:e3. doi: 10.1016/j.oraloncology.2017.02.001. Epub 2017 Feb 12. No abstract available.

PMID:
28202215
24.

Correction: Multispectral Imaging of T and B Cells in Murine Spleen and Tumor.

Feng Z, Jensen SM, Messenheimer DJ, Farhad M, Neuberger M, Bifulco CB, Fox BA.

J Immunol. 2017 Feb 15;198(4):1759. doi: 10.4049/jimmunol.1601990. No abstract available.

25.

Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.

Ng SSM, Nagy BA, Jensen SM, Hu X, Alicea C, Fox BA, Felber BK, Bergamaschi C, Pavlakis GN.

Clin Cancer Res. 2017 Jun 1;23(11):2817-2830. doi: 10.1158/1078-0432.CCR-16-1808. Epub 2016 Dec 16.

26.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.

Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S.

Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.

27.

Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.

Yu G, Li Y, Cui Z, Morris NP, Weinberg AD, Fox BA, Urba WJ, Wang L, Hu HM.

Sci Rep. 2016 Nov 22;6:37558. doi: 10.1038/srep37558.

28.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

29.

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.

Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, Capone M.

J Transl Med. 2016 Sep 20;14:273. doi: 10.1186/s12967-016-1029-z.

30.

Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.

Bryan RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2016 Oct;61:166-76. doi: 10.1016/j.oraloncology.2016.08.020. Epub 2016 Sep 7. Review. Erratum in: Oral Oncol. 2017 Mar;66:e3.

PMID:
27614589
31.

Pyrimidine Pathway-Dependent and -Independent Functions of the Toxoplasma gondii Mitochondrial Dihydroorotate Dehydrogenase.

Hortua Triana MA, Cajiao Herrera D, Zimmermann BH, Fox BA, Bzik DJ.

Infect Immun. 2016 Sep 19;84(10):2974-81. doi: 10.1128/IAI.00187-16. Print 2016 Oct.

32.

Phenotypes Associated with Knockouts of Eight Dense Granule Gene Loci (GRA2-9) in Virulent Toxoplasma gondii.

Rommereim LM, Bellini V, Fox BA, Pètre G, Rak C, Touquet B, Aldebert D, Dubremetz JF, Cesbron-Delauw MF, Mercier C, Bzik DJ.

PLoS One. 2016 Jul 26;11(7):e0159306. doi: 10.1371/journal.pone.0159306. eCollection 2016.

33.

Secretion of Rhoptry and Dense Granule Effector Proteins by Nonreplicating Toxoplasma gondii Uracil Auxotrophs Controls the Development of Antitumor Immunity.

Fox BA, Sanders KL, Rommereim LM, Guevara RB, Bzik DJ.

PLoS Genet. 2016 Jul 22;12(7):e1006189. doi: 10.1371/journal.pgen.1006189. eCollection 2016 Jul.

34.

OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer.

Montler R, Bell RB, Thalhofer C, Leidner R, Feng Z, Fox BA, Cheng AC, Bui TG, Tucker C, Hoen H, Weinberg A.

Clin Transl Immunology. 2016 Apr 15;5(4):e70. doi: 10.1038/cti.2016.16. eCollection 2016 Apr.

35.

Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine.

Page DB, Hulett TW, Hilton TL, Hu HM, Urba WJ, Fox BA.

J Immunother Cancer. 2016 May 17;4:25. doi: 10.1186/s40425-016-0130-4. eCollection 2016. Review.

36.

The Toxoplasma gondii Rhoptry Kinome Is Essential for Chronic Infection.

Fox BA, Rommereim LM, Guevara RB, Falla A, Hortua Triana MA, Sun Y, Bzik DJ.

MBio. 2016 May 10;7(3). pii: e00193-16. doi: 10.1128/mBio.00193-16.

37.

Attenuated Toxoplasma gondii therapy of disseminated pancreatic cancer generates long-lasting immunity to pancreatic cancer.

Sanders KL, Fox BA, Bzik DJ.

Oncoimmunology. 2015 Oct 29;5(4):e1104447. eCollection 2016 Apr.

38.

Multispectral Imaging of T and B Cells in Murine Spleen and Tumor.

Feng Z, Jensen SM, Messenheimer DJ, Farhad M, Neuberger M, Bifulco CB, Fox BA.

J Immunol. 2016 May 1;196(9):3943-50. doi: 10.4049/jimmunol.1502635. Epub 2016 Mar 18. Erratum in: J Immunol. 2017 Feb 15;198(4):1759.

39.

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA; Cancer Immunotherapy Trials Network (CITN).

J Immunother Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016. Review.

40.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

41.

Immune Monitoring Technology Primer: protein microarray ('seromics').

Yuan J, Wang E, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:2. doi: 10.1186/s40425-016-0106-4. eCollection 2016. No abstract available.

42.

Intravacuolar Membranes Regulate CD8 T Cell Recognition of Membrane-Bound Toxoplasma gondii Protective Antigen.

Lopez J, Bittame A, Massera C, Vasseur V, Effantin G, Valat A, Buaillon C, Allart S, Fox BA, Rommereim LM, Bzik DJ, Schoehn G, Weissenhorn W, Dubremetz JF, Gagnon J, Mercier C, Cesbron-Delauw MF, Blanchard N.

Cell Rep. 2015 Dec 15;13(10):2273-86. doi: 10.1016/j.celrep.2015.11.001. Epub 2015 Nov 25.

43.

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.

Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ.

Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. Review.

PMID:
26614363
44.

Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma.

Bell RB, Leidner R, Feng Z, Crittenden MR, Gough MJ, Fox BA.

J Oral Maxillofac Surg. 2015 Dec;73(12 Suppl):S107-15. doi: 10.1016/j.joms.2015.05.026. Review. No abstract available.

PMID:
26608138
45.

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.

Feng Z, Puri S, Moudgil T, Wood W, Hoyt CC, Wang C, Urba WJ, Curti BD, Bifulco CB, Fox BA.

J Immunother Cancer. 2015 Oct 20;3:47. doi: 10.1186/s40425-015-0091-z. eCollection 2015.

46.

Editorial: Advances in Combination Tumor Immunotherapy.

Curran MA, Fox BA, Redmond WL.

Front Oncol. 2015 Sep 22;5:198. doi: 10.3389/fonc.2015.00198. eCollection 2015. No abstract available.

47.

Parasite Manipulation of the Invariant Chain and the Peptide Editor H2-DM Affects Major Histocompatibility Complex Class II Antigen Presentation during Toxoplasma gondii Infection.

Leroux LP, Nishi M, El-Hage S, Fox BA, Bzik DJ, Dzierszinski FS.

Infect Immun. 2015 Oct;83(10):3865-80. doi: 10.1128/IAI.00415-15. Epub 2015 Jul 20.

48.

Immunoprofiling for prognostic assessment of colon cancer: a novel complement to ultrastaging.

Lavotshkin S, Jalas JR, Torisu-Itakura H, Ozao-Choy J, Lee JH, Sim MS, Stojadinovic A, Wainberg Z, Bifulco CB, Fox BA, Bilchik AJ.

J Gastrointest Surg. 2015 Jun;19(6):999-1006. doi: 10.1007/s11605-015-2759-6. Epub 2015 Mar 26.

49.

Preamble to the 2015 SITC immunotherapy biomarkers taskforce.

Butterfield LH, Disis ML, Fox BA, Khleif SN, Marincola FM.

J Immunother Cancer. 2015 Mar 24;3:8. doi: 10.1186/s40425-015-0052-6. eCollection 2015.

50.

Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.

Sanders KL, Fox BA, Bzik DJ.

Cancer Immunol Res. 2015 Aug;3(8):891-901. doi: 10.1158/2326-6066.CIR-14-0235. Epub 2015 Mar 24.

Supplemental Content

Support Center